title: Comments on Cooper et al.'s review on strategies to mitigate dissociative and psychotomimetic effects from ketamine when used as a fast-acting antidepressant.
authors.affiliation: a Dunedin School of Medicine , Otago , New Zealand.
authors.forename: Paul
authors.initials: P
authors.lastname: Glue
authors.affiliation: b School of Psychiatry , University of New South Wales & Black Dog Institute , Sydney , Australia.
authors.forename: Colleen
authors.initials: C
authors.lastname: Loo
authors.affiliation: c The George Institute for Global Health, the University of Sydney , Sydney , Australia.
authors.forename: Anthony
authors.initials: A
authors.lastname: Rodgers
authors.affiliation: b School of Psychiatry , University of New South Wales & Black Dog Institute , Sydney , Australia.
authors.forename: Verònica
authors.initials: V
authors.lastname: Gálvez
authors.affiliation: d School of Medicine , University of Adelaide , Adelaide , Australia.
authors.forename: Andrew A
authors.initials: AA
authors.lastname: Somogyi
authors.affiliation: b School of Psychiatry , University of New South Wales & Black Dog Institute , Sydney , Australia.
authors.forename: Philip B
authors.initials: PB
authors.lastname: Mitchell
mesh_terms: D000928:Antidepressive Agents; D003865:Major Depressive Disorder; D018691:Excitatory Amino Acid Antagonists; D006801:Humans; D007649:Ketamine
chemical_list: D000928:Antidepressive Agents; D018691:Excitatory Amino Acid Antagonists; D007649:Ketamine